Evaluation of Antibiotic Tolerance in *Pseudomonas aeruginosa* for Aminoglycosides and its Predicted Gene Regulations Through In-silico Transcriptomic Analysis

Abishek Kumar¹, Bency Thankappan², Angayarkanni Jayaraman², Akshita Gupta¹

1. Department of Microbiology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education (MAHE), Manipal, India
2. Department of Microbial Biotechnology, Bharathiar University, Coimbatore, India

Author information

Corresponding author: Mr. Abishek kumar. B, M.Sc.

Affiliation: Department of Microbiology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education (MAHE), Manipal, India

Current affiliation: Project Associate, Department of Genetics and Molecular Biology, Vision Research Foundation, Sankara Nethralaya, Chennai, India

Email: abishek77@hotmail.com

Tel: +91 8015216350, +91 9080310146

Running title: *In vitro* study of amikacin, gentamicin, and tobramycin in *P. aeruginosa*

Abstract

Pseudomonas aeruginosa causes chronic infections like cystic fibrosis, endocarditis, bacteremia and sepsis, which are life-threatening and difficult to treat. The lack of antibiotic response in *P. aeruginosa* is due to adaptive resistance mechanism, which prevents the entry of antibiotics into cytosol of the cell to achieve tolerance. Among different groups of antibiotics, aminoglycosides are used as a parental antibiotic for treatment of *P. aeruginosa*. This study aims to determine the kinetics of antibiotic tolerance and gene expression changes in *P. aeruginosa* exposed to amikacin, gentamicin, and tobramycin. These antibiotics were exposed to *P. aeruginosa* at their MICs and the experimental setup was monitored till 72 hours, followed by the measurement of optical density in the interval of every 12 hours. The growth of *P. aeruginosa* in MICs of antibiotics represents the kinetics of antibiotic tolerance in amikacin, gentamicin, and tobramycin. Transcriptomic profile of antibiotic exposed *P. aeruginosa* PA14 was taken from Gene Expression Omnibus (GEO), NCBI as microarray datasets. The gene expressions of two datasets were compared by test versus control. Tobramycin exposed *P. aeruginosa* failed to develop tolerance in MICs 0.5µg/mL, 1µg/mL and 1.5µg/mL. Whereas amikacin and gentamicin treated *P. aeruginosa* developed tolerance in MICs. This depicts the superior *in vitro* response of tobramycin over the gentamicin and amikacin. Further, *in silico* transcriptomic analysis of tobramycin treated *P. aeruginosa* resulted in low expression of 16s rRNA Methyltransferase E, B & L, alginate biosynthesis genes and several proteins of Type 2 Secretory System (T2SS) and Type 3 Secretory System (T3SS).

The Differentially Expressed Genes (DEGs) of alginate biosynthesis, and RNA Methyltransferases suggests increased antibiotic response and low probability of developing resistance. The use of tobramycin as a parental antibiotic with its synergistic combination might combat *P. aeruginosa* with increased response.

Keywords

Adaptive resistance, antibiotic tolerance, *in vitro* exposure, aminoglycoside, *Pseudomonas aeruginosa*, Differentially Expressed Genes (DEGs), transcriptomic analysis.

1. Introduction

P. aeruginosa is an opportunistic pathogen, causes chronic infections which are difficult to treat because of the limited response to antimicrobials and emergence of antibiotic resistance during therapy[1]. Multi-drug resistance (MDR) in *P. aeruginosa* is increasing due to over-exposure to antibiotics[2]. It is developed by various physiological and genetic mechanisms, which includes multidrug efflux pumps, beta-lactamase production, outer membrane protein (porin) loss and target mutations. In hospitals, MRD *P. aeruginosa* are concurrently resistant to ciprofloxacin, imipenem, ceftazidime and piperacillin-tazobactam in most of the cases, which limits the treatment options[3].

Aminoglycosides are major group of antibiotics with potential bacteriocidal effect for the treatment of *Pseudomonas* infections. They are either used alone or in combination to treat various infections to overcome drug resistance, particularly in cystic fibrosis patients[4], and infective endocarditis[5]. In the face of systemic infection with shock/sepsis, antimicrobial therapy should consist of two antimicrobial agents, with one of these being an aminoglycoside[6], because it exhibits concentration-dependent bactericidal activity and produce prolonged post-antibiotic effects[7].

β -lactam antibiotic plus an aminoglycoside is the commonly used synergistic combinations for treatment of clinical infections. Other combinations are fluoroquinolone & aminoglycosides and

tetracycline & aminoglycosides. Clinical isolates show high percent of susceptibility to aminoglycosides than the other first-line antibiotics[8]. Despite high susceptibility to aminoglycosides in clinical isolates, *P. aeruginosa* exhibits physiological adaptations to the antibiotics which results in less response to its synergistic combinations.

P. aeruginosa thrives in the inhibitory concentration of antibiotics gradually and acquires adaptive resistance, which makes the treatment more complicated[9]. Adaptive resistance mechanism was characterized by modification of the cytoplasmic membrane, condensation of membrane proteins and reduction of phospholipid content[10] which reduces penetration of antibiotics into the plasma membrane. Studies shows that the adaptive resistance can also develop by up-regulation of efflux pumps especially, MexXY-OprM[11].

Among immunocompromised patients, *P. aeruginosa* are favored to adapt the administered antibiotics and enable better survival of the bacterial generation by emerging as physiologically resistant groups[12]. Adaptive resistance is developed due to rapid transcriptomic alteration in response to antibiotic[13]. Better understanding of the kinetics and transcriptomic changes during antibiotic exposure can develop scientific insight on the adaptive resistance mechanism in *P. aeruginosa*[13,14]. On this background our study was designed for better understanding of adaptive resistance in *P. aeruginosa* for gentamicin, amikacin and tobramycin which are commonly used aminoglycosides as first line antibiotics.

2. Materials and Methods

2.1 Broth Dilution Method

Minimum Inhibitory Concentrations (MICs) of *P. aeruginosa* ATCC 27853 was determined by broth dilution method as per the Clinical and Laboratory Standards Institute (CLSI) guidelines. MIC assay was performed for gentamicin, amikacin, and tobramycin (purchased from Sigma Aldrich) with log phase culture (5×10^8 CFU/mL) in Mueller Hinton Broth (MHB) using 96-well microtiter plate. The final optical density (OD) was determined in Epoch™ Microplate spectrophotometer at 600nm.

2.2 *In vitro* exposure of antibiotics to *P. aeruginosa*

From the recorded MIC values, *P. aeruginosa* was inoculated in 10 mL MHB in a Tarsons tube with corresponding antibiotic concentrations after adjusting the cell density to OD₆₀₀ 0.26 (in log phase). The experiment set up was observed for 72 hours. *P. aeruginosa* was inoculated in antibiotic concentrations 0.5µg/mL, 1µg/mL & 1.5µg/mL for gentamicin & tobramycin. For amikacin, 1µg/mL, 2µg/mL & 3µg/mL antibiotic concentrations were taken. All antibiotic concentrations taken were based on MICs determined for *P. aeruginosa* ATCC 27853. The experimental condition was incubated at 37°C with optimal shaking of 74rpm. At every 12 hours the turbidity was monitored by measuring OD₆₀₀ in Epoch™ microtiter plate reader[14][15]. The tube with growth were sub-cultured in nutrient agar. The colonies were conformed for *P.*

aeruginosa by Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) automated identification system (VITEK® MS, BioMérieux) by following the standard procedure for sample preparation[16].

2.3 In silico transcriptomic analysis

2.3.1 Retrieval of microarray datasets

The differential gene expression analysis was performed by exploring microarray datasets published in Gene Expression Omnibus (GEO) NCBI, available as accessible series no. [GSE9991](#) and [GSE9989](#). Two datasets 1.) Tobramycin treated planktonic culture of *P. aeruginosa* (GSE9991) and 2.) Tobramycin treated *P. aeruginosa* biofilm (GSE9989) were analyzed. In [GSE9991](#), planktonic culture of PA14 was exposed to 5 µg/mL tobramycin for 30 minutes at 37°C. Two samples GSM252561 and GSM252562 of tobramycin treated PA14 planktonic culture was taken as test, which was compared to 2 samples GSM252559 and GSM252560 of unexposed PA14 planktonic culture as control. [GSE9989](#) consist of 6 samples, in which 3 samples GSM252496, GSM252501 and GSM252505 of unexposed *P. aeruginosa* biofilm were taken as control and 3 samples GSM252506, GSM252507 and GSM252508 of Tobramycin exposed *P. aeruginosa* biofilm was taken as test. Biofilms were grown on CFBE41o- cells in culture for 9 hours in MEM/0.4% arginine. Replicate samples were then incubated in the presence or absence of 500 µg/mL tobramycin for 30 minutes[17].

In the published datasets, before RNA harvesting, cells were washed several times in 2 ml PBS to remove antibiotics. The RNA was extracted using RNeasy RNA isolation kit. Bacterial RNA was then purified using MicrobEnrich kit, to exclude mammalian RNA. The purified RNA was subjected to cDNA synthesis followed by microarray preparation according to Affymetrix - Genechip *P. aeruginosa* Genome Array Expression Analysis Protocol[17].

2.3.2 Differential gene expression analysis

In the microarray datasets, raw data available as platform file was extracted, formatted, and uploaded as input data in NetworkAnalyst 3.0 (<https://www.networkanalyst.ca/>). In NetworkAnalyst 3.0, organism ID – *P. aeruginosa*, data type – intensity table (Microarray data) options were selected, and probe summarization was performed by multi-array average algorithm. The raw data was preprocessed by removing unannotated genes, and datasets were normalized by log2 transformation. By Linear Models for Microarray Analysis (Limma) statistical package, datasets were subjected to specific comparison by its test versus control samples to determine log2 fold change (LogFc) between two groups. To identify significant DEGs, the datasets were filtered by significant threshold cutoff of P-value ≤ 0.05 [18].

2.3.3 Gene Ontology (GO) and functional enrichment analysis

PANTHER Classification System (<http://pantherdb.org/>)[19] and DAVID Bioinformatics Resources 6.8 (<https://david.ncifcrf.gov/>)[20] computational tools were used for further

downstream analysis of significant DEGs. Gene ontology was performed in PANTHER for functional classification of DEGs under three categories which includes, molecular functions, biological process, and protein class. For enrichment analysis of significant DEGs, DAVID Bioinformatics Resources 6.8 tool was used. The databases selected for enrichment analysis in DAVID were KEGG Pathway, InterPro, UniProtKB, and SMART. Minimum threshold gene counts of ≥ 2 and EASE Score of 0.1 were set as cut off to filter and enrichments of P-value ≤ 0.05 and false discovery rate (FDR) ≤ 0.05 were only considered for the study. In the functional annotation clusters, enrichment score of 2.0 were set as threshold to select enriched clusters.

Further, target genes were annotated functionally using Pseudomonas Genome DB (<http://pseudomonas.com/>)[21] and PseudoCyc (<http://www.pseudomonas.com:1555/>)[22] to determine the protein and molecular interactions of DEGs based on previously published resources.

3.Results

3.1.Broth Dilution Method

MICs of gentamicin, amikacin and tobramycin for *P. aeruginosa* (ATCC 27853) were 0.5 µg/mL, 1.5 µg/mL and 0.5 µg/mL.

3.2.*In vitro* exposure of antibiotics to *P. aeruginosa*

The initial OD₆₀₀ of the bacterial culture was ~0.26 in all the tubes and after 12 hours the OD₆₀₀ dropped to ~0.13. In 0.5 µg/mL & 1 µg/mL of gentamicin (Figure 1) and 1 µg/mL & 2 µg/mL of amikacin (Figure 3) tubes, OD₆₀₀ increased exponentially after 24 hours. After 48 hours, the bacterial growth attained the initial OD₆₀₀ ~0.26 (Figures 1 and 3) and the cells resumed active growth after the post-antibiotic effect. In tobramycin and higher concentrations of gentamicin and amikacin tubes, after 12 hours OD₆₀₀ further declined, and no growth were observed till 72 hours (Figures 1, 2 and 3). The growth in 1 µg/mL & 2 µg/mL of amikacin and 0.5 µg/mL & 1 µg/mL of gentamicin tubes were confirmed as *P. aeruginosa* by MALDI-TOF automated identification system, based on the peptide mass fingerprint matching.

3.3.Differential gene expression analysis

In GSE9991, among 125 of DEGs 53 genes were upregulated and 72 were downregulated. In GSE9989, a total of 307 genes were differentially expressed in which 52 genes were upregulated and 255 genes were downregulated. Distribution of DEGs in both the datasets were represented in

volcano plot (Figure 4). Targeted DEGs in the study were 17 from GSE9991 and 22 from GSE9989 (Table 1&2).

3.4. Gene Ontology

Gene Ontology hits of DEGs in the functional classification system of PANTHER includes: 1) Molecular functions - Catalytic activity (GO:0003824), binding (GO:0005488), transcriptional regulator (GO:0098772) and transporter activity (GO:0005215). 2) Biological process - Biological regulations (GO:0065007), cellular process (GO:0009987), localization (GO:0051179), metabolic process (GO:0008152). 3) Protein classes - Nucleic acid metabolism protein (PC00171), gene-specific transcriptional regulator (PC00264), carrier protein (PC00219), and transporter protein (PC00227).

3.5. Functional enrichment analysis

The DEGs enriched in the functional pathways is represented in (Figure 5). DEGs enriched in the similar pathways were clustered into groups as functional annotation clusters with significant enrichment score (Table 3). The targeted DEGs were enriched in RNA Methyltransferases, 16S rRNA 7-methylguanosine methyltransferase, alginate biosynthesis, repressors for alginate synthesis, transcriptional repressor of SOS response, type II secretory proteins, type II transport domains, translocation protein in type III secretion and type III export protein.

4. Discussion

The experimental setup of *in vitro* exposure of antibiotic to *P. aeruginosa* reflects the antibiotic tolerance in chronic infections, where the response to antimicrobials diminishes due to development of adaptive resistance. Among the antibiotics evaluated for tolerance in *P. aeruginosa*, tobramycin exhibited a superior post-antibiotic effect in all MICs and was observed to be more effective by suppressing the antibiotic tolerance mechanism. Further, in silico analysis of DEGs in microarray datasets mimicking our experimental condition exposed the possible effectiveness of tobramycin in antibiotic tolerance.

In the microarray datasets, the Gene Ontological classification enabled preliminary classification of DEGs in key categories. The genes of RNA Methyltransferase and methylation metabolism were enriched in catalytic activity (GO:0003824) and nucleic acid metabolism (PC00171). Regulatory genes for alginate biosynthesis pathway were observed in transcriptional regulator (GO:0098772). Other categories like transporter activity (GO:0005215), localization (GO:0051179), carrier protein (PC00219) and transporter protein (PC00227) contain genes coding for T2SS and T3SS proteins.

Among the functional enrichments observed in GSE9991 and GSE9989 datasets, the following enrichments play a significant role in antibiotic tolerance and virulence of *P. aeruginosa*. Methylation of 16s rRNA by Methyltransferase is a common mechanism of resistance to

aminoglycosides leading to loss of affinity of the drug to the target[23]. In GSE9991, **RNA Methyltransferases**: PA0419, a Ribosomal RNA small subunit methyltransferase E which methylates 16s rRNA bases in 30s subunit was downregulated in the test samples. PA0017 and PA3680 genes of class B and J methyltransferase also lags expression. In GSE9989, **16S rRNA 7-methylguanosine methyltransferase**: gidB belongs to Methyltransferase G, which involves in methylation of 7th nucleotide guanosine, confers resistance to aminoglycoside by decreasing the binding affinity to its target[24]. Low expression of gidB (LogFc -3.32) and the gene expression profile of Methyltransferases suggest low incidence of resistance development during tobramycin exposure. The following observation also extend the insights in adaptive resistance mechanism and the possibility of regulation control of RNA Methyltransferases by *P. aeruginosa* during antibiotic exposure.

In chronic infections caused by *P. aeruginosa*, biofilm formation is common during the course of infection[25], which confers additional resistance from host defenses and antibiotics[26]. Some antibiotics are involved in the up-regulation of genes that are responsible for induction of alginate production (mucopolysaccharide with an altered LPS and lipid A) which results in reduced antigen presentation to the immune system[27]. In addition, biofilms of *P. aeruginosa* also contributes to antibiotic tolerance and the regulations of several biofilm forming genes will affect the persistence of the cells in antibiotics[28]. In GSE9991, **Alginate Biosynthesis**: algL is a lyase precursor, that participates in catabolic activity of alginic acid, which leads to deconstruction of alginate

complex[29] was highly expressed. Regulatory protein of alginate biosynthesis genes, algR [30] declined in expression. psIF was low expressed (LogFc -1.03) which is one among glycosyltransferase family, involved in extracellular polysaccharide biosynthetic pathway[31]. In GSE9989, **Repressors for alginate synthesis:** algU is the sigma factor for alginate biosynthesis genes. mucA codes for anti-sigma factor and mucB is a negative regulator of algU[32]. High expression of mucA (LogFc 4.09) and mucB (LogFc 1.15) may downregulate the alginate biosynthesis. The following transcriptional changes observed would possibly affect the alginate production to significant level in the presence of tobramycin treatment.

Previous studies suggest that toxin-antitoxin system mediates persister cells in antibiotics. Although, studies in E.coli show evidence for the mechanism[33], it is not clear in *P. aeruginosa*. Some of the DEGs were linked to suppress proteins of type II secretion system and type III secretion system, which participates in virulence activity of *P. aeruginosa*. In GSE9991, **Type II Secretary Proteins:** PA2677, PA2672 and PA0687 engage in catalytic and transporter protein activity was downregulated. Other transporter domains xcpR, xcpU, xcpV, xcpX, xcpY, xcpZ, tadB and tadD were also low expressed[34], affecting the T2SS. In GSE9989, **Type II Transport Domains:** xcpQ, xcpS, xcpT, xcpU, xcpV, xcpW, xcpX and xcpY which involves in efflux of toxin from xcpR, a cytosolic domain was down-regulated affecting the export of T2SS[35]. **Translocation protein in type III secretion:** pscQ, pscP and pscR are translocation protein of type III secretion system, which translocate the toxin across the host cell cytoplasmic membrane.

Downregulation of pscQ negatively impact the toxin delivery to cytosol of host cell. **Type III**

Export protein: pscE, pscF, pscG, pscH, pscI, pscJ, pscK are the export proteins of type III secretion system present in cytoplasmic membrane which transfers the toxin from cytosolic domain to MS ring of basal body[35]. Low expression of all these proteins, prevents toxins to reach filament, from where it is translocated into host cell. Following transcriptomic changes suggests the suppression of toxin port systems (T2SS and T3SS), which may reduce the virulence of the organism during tobramycin treatment.

Overuse of antibiotics hiked up transcriptional regulation, favoring adaptive resistance which out-turns the fall in antibiotic activity over time[36]. This study suggests the use of tobramycin for treatment of chronic *pseudomonas* infection, as *P. aeruginosa* failed to develop adaptive resistance in tobramycin and exhibited a positive transcriptomic regulation for antibiotic response. Tobramycin is restricted for systemic use due rise of creatinine level during initial days of therapy. Intensity of nephrotoxicity between aminoglycosides is poorly understood. Recent cohort study on, nephrotoxicity suggested that, tobramycin has less comparative toxicity over gentamicin[37]. Considering the *in vivo* drug response and predisposing factors, tobramycin one among the option might enable a better treatment alternative from the current drug combinations.

Transcriptional alterations in microbes are dynamic event triggered by environmental changes, which out-turns the increase in adaptive resistance. Although, adaptive resistance involves in hike of baseline MIC of the bacteria over time, genetic resistance is a function of time. It takes several

generations of the bacteria to achieve genotypic resistance. The methodology of constantly switching antibiotics through *in vitro* exposure of antibiotics would enable us in deciphering which clinical isolates would be physiologically resistant, leading to alternative aminoglycoside treatment for combating chronic infections.

Figures and Tables

Genes	Log Fc
PA2677	-2.21809
PA0687	-1.44816
PA2672	-1.23836
xcpR	-0.28436
xcpU	-0.50274
xcpV	-0.19849
xcpY	-0.22214
xcpZ	-0.21626
tadB	-0.16973
tadD	-0.25359
algR	-0.35921
algL	0.640009
pslF	-1.03452
PA1839	2.200892
PA0419	-0.92439
PA0017	-0.33728
PA3680	-0.34165

Table 1. List of target DEGs and its log fold change of expression in tobramycin treated planktonic *P. aeruginosa* (GSE9991)

Genes	Log Fc
mucA	4.094536
mucB	1.155318
lexA	3.42962
gidB	-3.31909
pscQ	-2.35821
pscP	-3.64432
pscR	-3.11905
pscG	-1.75324
pscH	-1.52118
pscE	-3.84799
pscF	-1.3676
pscI	-2.27261
pscJ	-1.43567
pscK	-1.6767
xcpQ	-2.31778
xcpS	-1.40397
xcpT	-0.72049
xcpU	-1.33575
xcpV	-3.11543
xcpW	-0.69783
xcpX	-0.42221
xcpY	-0.5616

Table 2. List of target DEGs and its log fold change of expression in tobramycin treated *P. aeruginosa* biofilm (GSE9989)

Clusters	% Enriched	P-Value	Fold Enrichment	FDR
Cluster 1				
Bacterial secretion system	50.00	9.75E-21	16.68	2.93E-20
Protein secretion by type II secretion system	30.56	4.38E-15	43.27	8.77E-14
Protein transporter activity	27.78	1.65E-14	52.90	2.65E-13
Protein transport	27.78	4.30E-12	33.91	1.89E-10
Type II protein secretion system complex	22.22	1.21E-10	42.90	1.33E-09
Transport	27.78	2.72E-04	4.31	0.003997
				Cluster 1 Enrichment Score: 12.16
Cluster 2				
Type II protein secretion system complex	22.22	1.21E-10	42.90	1.33E-09
Prokaryotic N-terminal methylation site	13.89	5.95E-06	38.23	4.58E-04
Methylation	11.11	1.52E-04	35.91	0.003334
				Cluster 2 Enrichment Score: 6.32
Cluster 3				
Methyltransferase	13.89	7.52E-04	11.56	0.007267
rRNA processing	11.11	9.42E-04	19.69	0.007267
S-adenosyl-L-methionine	13.89	9.91E-04	10.75	0.007267
rRNA base methylation	8.33	0.002519	36.88	0.010077
Cytoplasm	22.22	0.009652	3.16	0.047188
Transferase	13.89	0.396132	1.53	0.977778
				Cluster 3 Enrichment Score: 2.06

Table 3: Functional annotations of the DEGs clustered into various groups with significant enrichment score. Derived from the source DAVID Bioinformatics Resources 6.8.

Figure 1: *In vitro* exposure of MICs 0.5µg/mL, 1µg/mL, and 1.5µg/mL of gentamicin to *P. aeruginosa*. The OD values depict the kinetics of adaptive resistance in the cell.

Figure 2: *In vitro* exposure of MICs 0.5 µg/mL, 1 µg/mL, and 1.5 µg/mL of tobramycin to *P. aeruginosa*. The OD values depict the kinetics of adaptive resistance in the cell.

Figure 3: *In vitro* exposure of MICs 1 µg/mL, 2 µg/mL, and 3 µg/mL of amikacin to *P. aeruginosa*. The OD values depict the kinetics of adaptive resistance in the cell.

Figure 4: Volcano plot representing the distribution of DEGs in tobramycin treated *P. aeruginosa*. The figure represents the degree of variation in the gene expression of *P. aeruginosa* after exposure of tobramycin.

Figure 5: Pathway enrichments of DEGs. The functional annotations of target DEGs were performed in the DAVID Bioinformatics Resources 6.8. and represented in graph with percentage of DEGs enriched in the pathway.

Funding Information

No funding for the above study.

Author Contributions

All the authors had contributed for the above study in several ways.

	Contributor 1	Contributor 2	Contributor 3	Contributor 4
Concepts	✓			
Design	✓	✓		
Definition of intellectual content			✓	✓
Literature search	✓	✓		
Experimental studies	✓	✓		
Data acquisition	✓			
Data analysis	✓			
Statistical analysis	✓			
Manuscript preparation	✓	✓		
Manuscript editing	✓	✓	✓	✓
Manuscript review		✓	✓	✓
Guarantor			✓	

Conflict of Interest

The authors declare that there is no conflict of interest.

Ethical Statement

The study did not involve any human or animal experimentations.

Acknowledgment

We would like to express our gratitude to Department of Microbial Biotechnology, Bharathiar University for the laboratory and technical support. We are thankful to Dr. Angayarkanni for guidance during the study period.

References:

- [1] Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant *Pseudomonas aeruginosa*: Comparison of risks associated with different antipseudomonal agents. *Antimicrob Agents Chemother* 1999;43:1379–82.
<https://doi.org/10.1128/aac.43.6.1379>.
- [2] Lynch JP, Zhanel GG, Clark NM. Emergence of Antimicrobial Resistance among *Pseudomonas aeruginosa* : Implications for Therapy. *Semin Respir Crit Care Med* 2017;38:326–45. <https://doi.org/10.1055/s-0037-1602583>.
- [3] Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage *Pseudomonas aeruginosa* infections. *Drugs Context* 2018;7:1–18. <https://doi.org/10.7573/dic.212527>.
- [4] Prayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: Therapeutic strategies and toxicity. *Curr Opin Pulm Med* 2010;16:604–10.
<https://doi.org/10.1097/MCP.0b013e32833eebfd>.
- [5] Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a β -lactam for the treatment of bacterial endocarditis: A meta-analysis of comparative trials. *J Antimicrob Chemother* 2006;57:639–47. <https://doi.org/10.1093/jac/dkl044>.
- [6] Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. *Chemotherapy* 2005;51:227–33. <https://doi.org/10.1159/000087452>.
- [7] DORNBUSCH K, OLOFSSON C, HOLM S. Postantibiotic effect and postantibiotic sub-mic effect of dirithromycin and erythromycin against respiratory tract pathogenic bacteria. *Apmis* 1999;107:505–13. <https://doi.org/10.1111/j.1699-0463.1999.tb01586.x>.

- [8] Javiya V, Ghatak S, Patel K, Patel J. Antibiotic susceptibility patterns of *Pseudomonas aeruginosa* at a tertiary care hospital in Gujarat, India. *Indian J Pharmacol* 2008;40:230–4. <https://doi.org/10.4103/0253-7613.44156>.
- [9] Karlowsky JA, Saunders MH, Harding GAJ, Hoban DJ, Zhanel GG. In vitro characterization of aminoglycoside adaptive resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1996;40:1387–93. <https://doi.org/10.1128/aac.40.6.1387>.
- [10] Gilleland LB, Gilleland HE, Gibson JA, Champlin FR. Adaptive resistance to aminoglycosides antibiotics in *Pseudomonas aeruginosa*. *J Med Microbiol* 1989;29:41–50. <https://doi.org/10.1099/00222615-29-1-41>.
- [11] Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, et al. MexXy-OprM efflux pump is necessary for adaptive resistance of *Pseudomonas aeruginosa* to aminoglycosides. *Antimicrob Agents Chemother* 2003;47:1371–5. <https://doi.org/10.1128/AAC.47.4.1371-1375.2003>.
- [12] Moradali MF, Ghods S, Rehm BHA. *Pseudomonas aeruginosa* lifestyle: A paradigm for adaptation, survival, and persistence. *Front Cell Infect Microbiol* 2017;7. <https://doi.org/10.3389/fcimb.2017.00039>.
- [13] Sequence T, *Pseudomonas A*. Transcriptome Sequence of Antibiotic-Treated *Pseudomonas aeruginosa*. *Am Soc Microbiol* 2019;8:1–2. <https://doi.org/10.1128/MRA.01367-18>.
- [14] Lonergan Z, Nairn B, Wang J, Hsu Y-P, Hesse L, Beavers W, et al. An *Acinetobacter baumannii*, Zinc-Regulated Peptidase Maintains Cell Wall Integrity during Immune-Mediated Nutrient Sequestration. *Cell Rep* 2019;26:2009-2018.e6.

<https://doi.org/10.1016/j.celrep.2019.01.089>.

- [15] Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. Altering the Proclivity towards Daptomycin Resistance in Methicillin-Resistant *Staphylococcus aureus* Using Combinations with Other Antibiotics. *Antimicrob Agents Chemother* 2012;56:5046 LP – 5053. <https://doi.org/10.1128/AAC.00502-12>.
- [16] A. M, J. C, T. M, U. K, I. R, P. I, et al. Evaluation of Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry in Comparison to 16S rRNA Gene Sequencing for Species Identification of Nonfermenting Bacteria. *J Clin Microbiol* 2008;46:1946–54. <https://doi.org/10.1128/JCM.00157-08>.
- [17] Anderson GG, Moreau-Marquis S, Stanton BA, O’Toole GA. In Vitro Analysis of Tobramycin-Treated *Pseudomonas aeruginosa* Biofilms on Cystic Fibrosis-Derived Airway Epithelial Cells. *Infect Immun* 2008;76:1423 LP – 1433. <https://doi.org/10.1128/IAI.01373-07>.
- [18] Xia J, Gill EE, Hancock REW. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. *Nat Protoc* 2015;10:823–44. <https://doi.org/10.1038/nprot.2015.052>.
- [19] Mi H, Thomas P. PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. *Methods Mol Biol* 2009;563:123–40. https://doi.org/10.1007/978-1-60761-175-2_7.
- [20] Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009;37:1–13. <https://doi.org/10.1093/nar/gkn923>.

- [21] Winsor GL, Griffiths EJ, Lo R, Dhillon BK, Shay JA, Brinkman FSL. Enhanced annotations and features for comparing thousands of *Pseudomonas* genomes in the *Pseudomonas* genome database. *Nucleic Acids Res* 2016;44:D646–53. <https://doi.org/10.1093/nar/gkv1227>.
- [22] Romero P, Karp P. PseudoCyc, A Pathway-Genome Database for *Pseudomonas aeruginosa*. *Microb Physiol* 2003;5:230–9. <https://doi.org/10.1159/000071075>.
- [23] Doi Y, Arakawa Y. 16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides. *Clin Infect Dis* 2007;45:88–94. <https://doi.org/10.1086/518605>.
- [24] Ogasawara N, Yoshikawa H. Genes and their organization in the replication origin region of the bacterial chromosome. *Mol Microbiol* 1992;6:629–34. <https://doi.org/10.1111/j.1365-2958.1992.tb01510.x>.
- [25] Yu S, Wei Q, Zhao T, Guo Y, Ma LZ. A survival strategy for *Pseudomonas aeruginosa* that uses exopolysaccharides to sequester and store iron to stimulate psl-dependent biofilm formation. *Appl Environ Microbiol* 2016;82:6403–13. <https://doi.org/10.1128/AEM.01307-16>.
- [26] Menendez A, Brett Finlay B. Defensins in the immunology of bacterial infections. *Curr Opin Immunol* 2007;19:385–91. <https://doi.org/10.1016/j.coi.2007.06.008>.
- [27] Li YH, Tian X. Quorum sensing and bacterial social interactions in biofilms. *Sensors* 2012;12:2519–38. <https://doi.org/10.3390/s120302519>.
- [28] Ciofu O, Tolker-Nielsen T. Tolerance and Resistance of *Pseudomonas aeruginosa* Biofilms to Antimicrobial Agents-How *P. aeruginosa* Can Escape Antibiotics. *Front Microbiol* 2019;10:913. <https://doi.org/10.3389/fmicb.2019.00913>.

- [29] Schiller NL, Monday SR, Boyd CM, Keen NT, Ohman DE. Characterization of the *Pseudomonas aeruginosa* alginate lyase gene (*algL*): Cloning, sequencing, and expression in *Escherichia coli*. *J Bacteriol* 1993;175:4780–9. <https://doi.org/10.1128/jb.175.15.4780-4789.1993>.
- [30] Deretic V, Konyecsni WM. Control of mucoidy in *Pseudomonas aeruginosa*: Transcriptional regulation of *algR* and identification of the second regulatory gene, *algQ*. *J Bacteriol* 1989;171:3680–8. <https://doi.org/10.1128/jb.171.7.3680-3688.1989>.
- [31] Jackson KD, Starkey M, Kremer S, Parsek MR, Wozniak DJ. Identification of *psl*, a locus encoding a potential exopolysaccharide that is essential for *Pseudomonas aeruginosa* PAO1 biofilm formation. *J Bacteriol* 2004;186:4466–75. <https://doi.org/10.1128/JB.186.14.4466-4475.2004>.
- [32] Qiu D, Eisinger VM, Rowen DW, Yu HD. Regulated proteolysis controls mucoid conversion in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 2007;104:8107–12. <https://doi.org/10.1073/pnas.0702660104>.
- [33] Kim Y, Wood TK. Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in *Escherichia coli*. *Biochem Biophys Res Commun* 2010;391:209–13. <https://doi.org/https://doi.org/10.1016/j.bbrc.2009.11.033>.
- [34] Korotkov K V., Sandkvist M, Hol WGJ. The type II secretion system: Biogenesis, molecular architecture and mechanism. *Nat Rev Microbiol* 2012;10:336–51. <https://doi.org/10.1038/nrmicro2762>.
- [35] Ma Q, Zhai Y, Schneider JC, Ramseier TM, Saier MH. Protein secretion systems of *Pseudomonas aeruginosa* and *P. fluorescens*. *Biochim Biophys Acta - Biomembr*

2003;1611:223–33. [https://doi.org/10.1016/S0005-2736\(03\)00059-2](https://doi.org/10.1016/S0005-2736(03)00059-2).

- [36] Sandoval-Motta S, Aldana M. Adaptive resistance to antibiotics in bacteria: A systems biology perspective. *Wiley Interdiscip Rev Syst Biol Med* 2016;8:253–67.

<https://doi.org/10.1002/wsbm.1335>.

- [37] van Maarseveen E, van Buul-Gast MC, Abdoellakhan R, Gelinck L, Neef C, Touw D. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. *J Antimicrob Chemother* 2014;69:2581–3.

<https://doi.org/10.1093/jac/dku175>.